Baseline characteristics
| Variable . | Subcategory . | n (%) . |
|---|---|---|
| Age (y, median, IQR) | 57 (47-63) | |
| Sex | Male | 73 (53%) |
| Female | 65 (47%) | |
| Study arm | KRd | 73 (53%) |
| R | 65 (47%) | |
| M protein isotype | IgG κ | 75 (54%) |
| IgG λ | 27 (19%) | |
| IgA κ | 16 (12%) | |
| IgA λ | 4 (3%) | |
| IgM κ | 1 (1%) | |
| IgM λ | 3 (2%) | |
| FLC κ | 10 (7%) | |
| FLC λ | 2 (2%) | |
| IMWG response at study entry | <VGPR | 16 (12%) |
| VGPR | 73 (53%) | |
| CR | 31 (22%) | |
| sCR | 18 (13%) | |
| MRD by NGS at study entry | Negative | 35 (25%) |
| Positive | 40 (29%) | |
| Not evaluated | 63 (46%) | |
| MRD by MFC at study entry | Negative | 82 (59%) |
| Positive | 39 (29%) | |
| Not evaluated | 17 (12%) | |
| ISS | 1 | 49 (35%) |
| 2 | 67 (48%) | |
| 3 | 22 (17%) | |
| Cytogenetic risk | Standard | 104 (75%) |
| High | 34 (25%) | |
| Time from ASCT (d, median, IQR) | 92.5 (76-114.3) |
| Variable . | Subcategory . | n (%) . |
|---|---|---|
| Age (y, median, IQR) | 57 (47-63) | |
| Sex | Male | 73 (53%) |
| Female | 65 (47%) | |
| Study arm | KRd | 73 (53%) |
| R | 65 (47%) | |
| M protein isotype | IgG κ | 75 (54%) |
| IgG λ | 27 (19%) | |
| IgA κ | 16 (12%) | |
| IgA λ | 4 (3%) | |
| IgM κ | 1 (1%) | |
| IgM λ | 3 (2%) | |
| FLC κ | 10 (7%) | |
| FLC λ | 2 (2%) | |
| IMWG response at study entry | <VGPR | 16 (12%) |
| VGPR | 73 (53%) | |
| CR | 31 (22%) | |
| sCR | 18 (13%) | |
| MRD by NGS at study entry | Negative | 35 (25%) |
| Positive | 40 (29%) | |
| Not evaluated | 63 (46%) | |
| MRD by MFC at study entry | Negative | 82 (59%) |
| Positive | 39 (29%) | |
| Not evaluated | 17 (12%) | |
| ISS | 1 | 49 (35%) |
| 2 | 67 (48%) | |
| 3 | 22 (17%) | |
| Cytogenetic risk | Standard | 104 (75%) |
| High | 34 (25%) | |
| Time from ASCT (d, median, IQR) | 92.5 (76-114.3) |
CR, complete response; FLC, free light chain; IMWG, International Myeloma Working Group; IQR, interquartile range; ISS, International Staging System; sCR, stringent complete repsonse; VGPR, very good partial response.